Ovarian Cancer Global Clinical Trials Review, H1, 2016

GlobalData
1725 Pages - GLDATA54476
$2,500.00

Summary

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Companies Mentioned

F. Hoffmann-La Roche Ltd.
AstraZeneca Plc
Sanofi
GlaxoSmithKline Plc
Merck & Co., Inc.
AbbVie Inc.
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Johnson & Johnson

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Ovarian Cancer Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Ovarian Cancer 30
May 02, 2016: Novogen Provides Update On Development Of Cantrixil 30
May 02, 2016: Celsion Announces Positive Data from the First Cohort of Patients in the OVATION Study 30
Apr 29, 2016: SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer 31
Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 32
Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting 33
Apr 21, 2016: OncoMed Announces Clinical Data for ipafricept to be Presented at the 2016 ASCO Annual Meeting 34
Apr 21, 2016: TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute 34
Apr 19, 2016: Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin and Doxil 35
Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 35
Apr 19, 2016: MacroGenics Presents Data from ROR1 x CD3 DART Preclinical Program at AACR Annual Meeting 2016 36
Apr 19, 2016: New class of small molecule drug, SI-2, has potential for improving cancer treatment 37
Apr 18, 2016: DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer 37
Apr 18, 2016: Morphotek Announces Publication of Phase 3 Results From MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients 38
Apr 17, 2016: Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel Neo-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016 39
Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting 39
Apr 12, 2016: Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer 40
Apr 07, 2016: TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine 40
Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer 41
Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) 41
Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 42
Mar 22, 2016: CytRx to Present New Data Using Its Proprietary LADR Technology at the 2016 American Association for Cancer Research Annual Meeting 43
Mar 21, 2016: Oncolytics Biotech Reports Data from Randomized Phase 2 Study of REOLYSIN in Ovarian Cancer 43
Mar 16, 2016: Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil at the AACR Annual Meeting 2016 44
Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting 46
Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 46
Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting 47
Mar 10, 2016: PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study 48
Mar 08, 2016: Innovative Approach to Ovarian Cancer Treatment Unveiled by Biomedical Scientists at the Lankenau Institute for Medical Research 49
Mar 04, 2016: Karyopharm’s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 49
Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators 50
Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 51
Feb 12, 2016: Celsion Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update 51
Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer 52
Clinical Trial Profile Snapshots 54
Appendix 1722
Abbreviations 1722
Definitions 1722
Research Methodology 1723
Secondary Research 1723
About GlobalData 1724
Contact Us 1724
Disclaimer 1724
Source 1725

List of Tables
Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7
Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 1723

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports